Lupin announced today that it has divested its U.S. Commercial Women`s Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women`s Health. Lupin`s U.S. Commercial Women`s Health Specialty Business is primarily focused on commercializing SOLOSEC� (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. Under the terms of the deal, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones. Powered by Capital Market - Live News

Lupin announced that the Annual General Meeting (AGM) of the company will be held on 2 August 2024.Powered by Capital Market - Live News

Lupin has allotted 42932 fully paid-up equity shares of a 2/- each under ESOP. In view of the above, the issued and paid-up capital of the Company has been increased to a 91,19,17,770 consisting of 45,59,58,885 equity shares of a 2/- each. Powered by Capital Market - Live News

Lupin has allotted 43,475 fully paid-up equity shares under ESOP on 21 June 2024. In view of the above, the issued and paid-up capital of the Company has been increased to a 91,18,31,906 consisting of 45,59,15,953 equity shares of a 2/- each. Powered by Capital Market - Live News

On 07 June 2024, Lupin entered into business transfer agreement with Lupin Life Sciences, a wholly owned subsidiary, to carve out, its trade generics business in India, as a going concern, on a slump sale basis. The said carve out will be effective 01 July 2024. Powered by Capital Market - Live News